Background: Vitamin B6 is involved in many biochemical reactions and might play a role in carcinogenesis. We summarized the evidence linking vitamin B6 to cancer risk. Methods: We conducted a systematic review of both observational and intervention studies investigating the relationship between vitamin B6 intake or blood levels of its bioactive form pyridoxal-5'-phosphate (PLP) and the risk of any type of cancer. Random-effects meta-analysis was used to calculate pooled relative risks (RRs) and their 95% confidence intervals (CIs) across studies for high vs low categories of vitamin intake or PLP levels. We also performed a random-effects dose-response metaanalysis. Results: We identified 121 observational studies (participants, n ¼ 1 924 506; cases, n ¼ 96 , 436) and nine randomized controlled trials (RCTs; participants, n ¼ 34 911; cases, n ¼ 2539) considering 19 tumor sites. High intake of dietary (food only) vitamin B6 was statistically significantly associated with lower risk of all cancers (relative risk [RR] ¼ 0.78, 95% CI ¼ 0.73 to 0.84) and specific tumors, with special regard to gastrointestinal carcinomas (RR ¼ 0.68, 95% CI ¼ 0.61 to 0.75). An inverse association was also observed between high PLP levels and the risk of all cancers (RR ¼ 0.66, 95% CI ¼ 0.58 to 0.76) and single tumor sites, the most consistent results being those for gastrointestinal tumors (RR ¼ 0.56, 95% CI ¼ 0.48 to 0.65). There was a statistically significant inverse linear relationship between cancer risk and both vitamin B6 dietary intake and PLP levels. When total (food and supplements) intake was considered, the associations were weaker or null. Findings from RCTs did not support a protective effect of vitamin B6 against cancer, although this evidence was graded as low level. Conclusions: Epidemiological evidence supports the potential of vitamin B6 as a cancer risk reduction agent and the role of PLP as a cancer screening biomarker, especially for gastrointestinal tumors. However, inconsistent findings from total intake and intervention studies suggest that vitamin B6 might also be an indicator of other dietary protective micronutrients.
field. Here we systematically reviewed and meta-analyzed the evidence regarding the role of vitamin B6 intake and the circulating levels of its bioactive form (pyridoxal-5'-phosphate [PLP] ) in the risk of developing any type of cancer. To this aim, we considered both observational studies (both prospective and retrospective) and intervention trials. As regards the former, we performed a meta-analysis of high vs low categories of vitamin intake/level, as well as a dose-response meta-analysis; for the latter, we pooled the results of available randomized controlled trials (RCTs).
Methods

Search Strategy, Eligibility Criteria, and Data Extraction
Following the Meta-analysis Of Observational Studies in Epidemiology (MOOSE) (8) and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) (9) guidelines, we searched for studies dealing with the association between vitamin B6 intake or PLP peripheral blood (plasma or serum) levels and cancer risk in humans; to this aim, both prospective (cohort and nested case-control studies) and retrospective designs (case-control studies) were considered eligible. We also searched the international literature to find randomized controlled trials (RCTs) testing the hypothesis that pharmacological doses of vitamin B6 might reduce the incidence of cancer. No language restriction was applied. Exclusion criteria were data published in abstract form only and lack of risk estimates (or data necessary to calculate them).
A two-step search strategy was adopted. First, a systematic review was performed by querying Medline (via the PubMed gateway) and Web of Science databases until January 2016; the following search terms were used: ("vitamin B6" OR "pyridoxine" OR "PLP" OR "pyridoxal-5'-phosphate") AND ("cancer" OR "tumor" OR "carcinoma" OR "melanoma" OR "sarcoma" OR "lymphoma" OR "leukemia"). In the second phase, cited references from eligible articles were searched. In case of overlapping series, only the most updated version was included. Authors were contacted whenever unreported data were potentially useful to enable the inclusion of the study into the systematic review or to rule out data published in different articles but regarding overlapping series. When the same article reported findings separately from more than one data set (eg, men and women; premenopausal and postmenopausal women; colon and rectal cancer), we maintained and analyzed them separately.
The following data from eligible studies were independently extracted by two authors (SM and MB), disagreements being resolved by discussion and consensus: authors' names; country where the study was conducted; year of publication; numbers of cases (defined as patients diagnosed with cancer based on histological evaluation, cancer site being recorded whenever available) and participants; prevalent ethnicity (>80%); study design, tumor site, type of vitamin intake (dietary [food only] or total intake [dietary plus supplements]), adjustment for confounding factors, levels of exposure (quantiles of vitamin B6 intake and plasma levels), and measures of association (choosing those with the highest degree of control for potential confounding factors), along with their 95% confidence intervals (CIs) for the risk comparison between high and low categories as well as across more than two exposure levels (for both vitamin B6 intake and PLP blood concentration).
Statistical Analysis
Different measures of association quantifying the strength of association between exposure and outcome were expected: odds ratio for retrospective studies (such as case-control and nested case-control studies); rate ratio (incidence rate data) or risk ratio (cumulative incidence data) or hazard ratio (time to event data) for prospective studies (including RCTs). For simplicity, we used relative risk (RR) as a generic term to refer to all the above.
Summary relative risks (along with their corresponding 95% CIs) were calculated by performing random effects metaanalysis (using the DerSimonian and Laird inverse variance method) (10) . This analysis was utilized for pooling data comparing high vs low categories of exposure, such as highest vs lowest quantiles of vitamin B6 intake or PLP blood concentrations (observational studies), or intervention vs placebo/observational arms (RCTs).
Moreover, a dose-response meta-analysis was carried out to assess a linear trend between different exposure levels and cancer risk using a random effects meta-regression (11, 12) . The median level for each exposure category (ie, vitamin B6 daily intake or PLP blood level quantiles) was assigned to the corresponding RR for each study; then, we first pooled the study data and afterward estimated the dose-response model (taking into account the correlation between RRs within each study). A potential nonlinear relationship was investigated by means of a restricted cubic spline model with three knots at fixed percentiles (25th, 50th, and 75th); a P value for nonlinearity was calculated by testing the null hypothesis that the coefficient of the second spline is equal to 0 (12) .
To maximize clarity of data interpretation and reporting, findings on dietary (food only) and total (food and supplements) vitamin B6 intake were analyzed and described separately. We performed evaluation of heterogeneity, subgroup analyses, and examination for bias. Between-study heterogeneity (true variance of effect size across studies) was quantified using the Isquare statistic (which indicates the percentage of the variability in effect estimates due to true heterogeneity rather than withinstudy sampling error; low: <25%, intermediate: 25%-50%; high: >50%) and formally tested by means of the Cochran Q-test (13) .
Subgroup analysis by tumor site, study design (retrospective vs prospective), and ethnicity (Asian vs Caucasian/other) was performed, if data permitted; effect differences were formally tested by means of random effects meta-regression. In addition, the impact of number of cases examined, range of exposure (highest minus lowest category values), publication year, and study quality were verified by means of random effects meta-regression.
Publication and selection biases in meta-analysis are more likely to affect small studies, which also tend to be of lower methodological quality: This may lead to the so-called "small study effect," where the smaller studies show larger effects. A funnel plot was used to detect this effect, and asymmetry was formally investigated with the Egger linear regression approach (if at least 10 studies were available) (14) .
The alpha level of statistical significance was set at less than .05, except for the Cochran Q-test and the Egger test, for which a P value of less than .10 was considered statistically significant. All statistical analyses were performed with STATA 11.2/SE (StataCorp LP, College Station, TX). All statistical tests were two-sided.
Quality Assessment and Evidence Grading
Quality of observational studies was assessed by means of the Newcastle-Ottawa Scale (NOS), which assigns up to nine stars REVIEW to each study based on eight items grouped into three categories (selection, comparability, and exposure or outcome for case control or cohort studies, respectively) (15) . For intervention randomized trials, the Cochrane Collaboration's quality assessment tool was adopted to assign low, unclear, or high risk of bias to each study based on issues addressed by six domains (sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete data outcome; selective outcome reporting; and other sources of bias) (16) .
The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) system was employed to grade the quality of evidence into four levels: high, moderate, low, and very low (17) . Briefly, evidence from RCTs and observational studies start with a high and low rating, respectively. Then, quality can be downgraded by one (serious concern) or two levels (very serious concern) for the following reasons: study limitations (risk of bias), evidence for publication bias, indirectness (indirect population, intervention, control, outcomes), inconsistency (between-study statistical heterogeneity), and imprecision (confidence intervals crossing the unit, single trial). On the other side, quality can be upgraded for two main reasons: large beneficial effect (we considered risk reduction >30%) and dose-response relationship between treatment/exposure and risk.
Results
Search Findings
The literature search yielded 949 articles: Their screening led to the identification of 132 eligible articles reporting on 155 data sets (146 from observational studies and nine from randomized controlled trials) (Figure 1 Overall, data were available from 1 959 417 participants, including 98 975 cases affected with cancers originating from the following 19 sites: breast (n ¼ 33 934, 34.3%), colorectal (26 220, 26.5%), ovary (n ¼ 5816, 5.9%), prostate (n ¼ 5135, 5.2%), immune system (n ¼ 3837, 3.9%), unspecified site (n ¼ 3502, 3.5%), endometrium (n ¼ 3030, 3.1%), lung (n ¼ 3024, 3.1%), stomach (n ¼ 2937, 3.0%), esophagus (n ¼ 2684, 2.7%), pancreas (n ¼ 2290, 2.3%), kidney (n ¼ 2256, 2.3%), bladder (n ¼ 1559, 1.6%), oral cavity (n ¼ 754,0.8%), nasopharynx (n ¼ 600,0.6%), larynx (n ¼ 527,0.5%), cervix (n ¼ 357,0.4%), liver (n ¼ 297,0.3%), and brain (n ¼ 216,0.2%). Data came from 121 observational studies (participants, n ¼ 1 924 506, cases, n ¼ 96 436) and nine randomized controlled trials (RCTs; participants, n ¼ 34 911; cases, n ¼ 2539).
Observational Studies: Vitamin B6 Intake
Vitamin B6 intake and cancer risk were assessed in 121 studies (participants, n ¼ 1 902 712; cases, n ¼ 85 734), the design being retrospective and prospective in 73 (60.3%) and 48 studies, respectively (Supplementary Table 1 , available online). Based on the Newcastle-Ottawa Scale tool, study quality was maximal (nine stars) in most cases (n ¼ 70, 57.8%); lower-quality studies were graded with eight (n ¼ 42, 34.7%), seven (n ¼ 6, 4.9%), and six stars (n ¼ 3, 2.5%), respectively, the reasons for downgrading being suboptimal representativeness (n ¼ 33, 64.7%) or comparability (n ¼ 15, 29.4%), and mixed (n ¼ 3, 5.9%), respectively. 
REVIEW High vs Low Category Meta-Analysis
Considering dietary intake (studies, n ¼ 95; cases, n ¼ 34 861), a full list of results is available online (see Supplementary Table 4 and Supplementary Figure 1 , available online), whereas a summary of main findings is reported in Figure 2 . Higher vitamin B6 doses were associated with a statistically significantly reduced risk of any type of cancer (RR ¼ 0.78, 95% CI ¼ 0.73 to 0.84). There was no evidence of small study effect (Egger's test P ¼ .23), suggesting no publication bias. In the light of the remarkable between-study heterogeneity (I-squared ¼ 77%), we investigated its potential sources.
Subgroup analysis by cancer site showed that higher intake of dietary vitamin B6 was linked to a statistically significantly lower risk of esophageal (RR ¼ 0.57, 95% CI ¼ 0.47 to 0.69), pancreatic (RR ¼ 0.64, 95% CI ¼ 0.44 to 0.93), gastric (RR ¼ 0.66, 95% CI ¼ 0.57 to 0.76), colorectal (RR ¼ 0.72, 95% CI ¼ 0.61 to 0.84), and breast (RR ¼ 0.88, 95% CI ¼ 0.78 to 0.98) cancer, heterogeneity being low only for esophageal and gastric tumors (Figure 2 ). In contrast, meta-analysis suggested no evidence of association for the following tumor sites: lung, prostate, kidney, endometrium, ovary, and immune system. Pooling studies by tumor site, we observed a statistically significant association with the following groups: upper airway (oral cavity and nasopharynx and larynx: RR ¼ 0.46, 95% CI ¼ 0.33 to 0.63), urinary tract (kidney and prostate and bladder: RR ¼ 0.88, 95% CI ¼ 0.78 to 0.99), and gastrointestinal (esophagus and stomach and colorectal and pancreatic: RR ¼ 0.68, 95% CI ¼ 0.61 to 0.75), heterogeneity being low, moderate, and high, respectively.
In many circumstances, the evidence in favor of an association with cancer risk was weaker among prospective as compared with retrospective studies; for example, data on gastrointestinal tumors showed a lower risk among retrospective (RR ¼ 0.62, 95% CI ¼ 0.54 to 0.71) as compared with prospective (RR ¼ 0.81, 95% CI ¼ 0.70 to 0.94) series (meta-regression P interaction ¼.02) (Supplementary Table 4 , available online). Nevertheless, between-study heterogeneity did not decrease remarkably across studies with the same design (Supplementary Table 4 , available online).
Overall, subgroup analysis by ethnicity was not informative because of the small number of Asian studies (Supplementary  Table 4 , available online). Analogously, meta-regression, including number of cases examined, range of exposure (highest minus lowest category values), year of publication, and study quality, was not informative.
We then considered total (dietary and supplements) vitamin B6 intake (studies, n ¼ 49; cases, n ¼ 20 796). A full list of results is available online (Supplementary Table 5 (1498) 45 (12 145) 23 (8706) 95 (34 861) 9 (2321) 18 (11 456) 3 (2222) 4 (602) 9 (3664) 4 (1333) 6 (1442) 8 ( RR (955 Cl) P Table 6 , available online). In contrast, metaanalysis suggested no evidence of association for esophageal, lung, prostate, kidney, endometrial, and hematological tumors (Supplementary Table 6 , available online).
Pooling tumors by site, only gastrointestinal cancers were inversely associated with vitamin dietary intake (RR ¼ 0.94, 95% CI ¼ 0.92 to 0.96), with evidence of statistically significant heterogeneity (Figure 3, lower panel) . No such a relationship could be demonstrated for gynecological or urologic cancers. In some cases, the evidence in favor of a dose-response relationship was weaker among prospective as compared with retrospective studies, but the risk difference was statistically significant only when all sites where considered, which showed homogeneity across prospective studies. Finally, subgroup analysis by ethnicity was not informative.
As regards total vitamin intake (studies, n ¼ 43; participants, n ¼ 33 927), all results are available online (Supplementary Table  7 , available online). Trend meta-analysis showed a statistically significant association only with esophageal (RR ¼ 0.87, 95% CI ¼ 0.78 to 0.98) and gastrointestinal (RR ¼ 0.98, 95% CI ¼ 0.97 to 0.99) cancers, without evidence of heterogeneity or deviation from linearity. Subgroup analysis did not provide further insights.
Overall, in the light of the large protective effect coupled with the dose-response relationship but in the presence of between-study heterogeneity, the level of evidence supporting the association between vitamin B6 dietary intake and the risk of gastrointestinal cancers was graded as moderate.
Observational Studies: PLP Blood Levels
The relationship between circulating levels of vitamin B6 (measured as PLP concentration in the peripheral blood) and cancer risk was investigated in 25 studies (participants, n ¼ 20 858; cases, n ¼ 9671), the design being prospective in all studies but one and the ethnicity being Caucasian in all studies but one. Based on the Newcastle-Ottawa Scale tool, study quality was maximal (nine stars) in most cases (n ¼ 14, 56.0%); the remaining 11 studies were graded with eight stars, the reason for downgrading being suboptimal representativeness of the studied population. Table 8 , available online), whereas a summary of main findings is reported in Figure 4 . Data meta-analysis from all 25 studies (cases, n ¼ 2545) showed that higher vitamin B6 plasma levels were statistically significantly and inversely associated with the risk of any cancer site (RR ¼ 0.66, 95% CI ¼ 0.58 to 0.76). As the heterogeneity was remarkable (I-squared ¼ 51%), we searched for its potential sources.
High vs Low Category Meta-Analysis
A full list of results is available online (Supplementary
Subgroup analysis by tumor site led to the identification of a statistically significant association with colorectal (RR ¼ 0.56, 95% CI ¼ 0.46 to 0.67), pancreatic (RR ¼ 0.56, 95% CI ¼ 0.41 to 0.80), and lung (RR ¼ 0.50, 95% CI ¼ 0.38 to 0.67) cancers, with no between-study heterogeneity (I-squared ¼0%) (Supplementary Table 8 , available online). No statistically significant association was found for breast, prostate, or kidney tumor sites. When pooling cancer sites, the association between PLP levels and the risk of gastrointestinal tumors was large and highly statistically significant (RR ¼ 0.56, 95% CI ¼ 0.48 to 0.65), with no heterogeneity (I-squared ¼0%) (Supplementary Table 8 , available online). (743) 3 (224) 5 (425) 1 (59) 3 (179) 25 (2545) 5 (379) 1 (244) 6 ( Including predefined covariates in a meta-regression model did not yield noteworthy results.
Dose-Response Meta-Analysis
Overall, in light of the large protective effect coupled with the dose-response relationship and the lack of heterogeneity, the level of evidence supporting the association between PLP levels and the risk of gastrointestinal cancers was graded as high.
Intervention Studies
Nine randomized controlled trials (RCTs) enrolling 34 911 participants (cases, n ¼ 2539) reported cancer incidence data among participants randomly assigned to regularly take supplemental vitamin B6 (see Supplementary Table 3 , available online, for 
REVIEW details)
. In all trials, vitamin B6 (daily dose ¼ 3 to 100 mg; mean treatment duration ¼ 2 to 7.3 years) was administered in combination with vitamin B12 and folate, vitamin combination being compared with placebo in all cases except one RCT, where high vs low doses of micronutrients (including vitamin B6) were compared (18) .
In no trial was the primary endpoint cancer risk; all studies focused instead on the incidence of cardiovascular events; in addition, participants were not taken from the general population but were rather patients affected with specific diseases (cardiovascular disease [n ¼ 8] or chronic renal failure [n ¼ 1]). This is the reason why no adjustment for cancer-related risk factors was applied in data analysis. As regards quality assessment, no trial was deemed at high risk of bias.
No single study found a statistically significant association between vitamin B6 intake and incidence of cancer (any site). Data meta-analysis showed no protective effect on the risk of any tumor (RR ¼ 1.03, 95% CI ¼ 0.94 to 1.13, P ¼ .47, I-squared ¼ 0.0%). Data on single tumor sites were available only in two RCTs, the findings of which were reported in a single pooled analysis (19) , and in a third study (20) reporting on different tumor sites; therefore, no site-specific meta-analysis could be performed.
In the RCT with the longest treatment duration and follow-up (7.3 years)-where women only were recruited-the investigators reported a 17% risk reduction for breast cancer (cases, n ¼ 154), although the result did not reach statistical significance (RR ¼ 0.83, 95% CI ¼ 0.60 to 1.14) (Supplementary Table 3 , available online). In the only two studies (19) where one of the four arms consisted of vitamin B6 alone, the intake of this vitamin was not associated with cancer (any site) risk (RR ¼ 1.11, 95% CI ¼ 0.87 to 1.41); however, during the second half of the follow-up time (ie, 3.2 years), participants were not treated with vitamin B6.
Overall, the level of evidence supporting the lack of protective effect of vitamin B6 against any cancer was graded as low because of the high risk of bias in terms of representativeness of the population, type of treatment, and study outcomes.
Discussion
We systematically reviewed and meta-analyzed the evidence regarding the relationship between vitamin B6 intake and blood levels with the risk of cancer. To this aim, we included both observational (prospective and retrospective) and intervention studies, gathering together the largest collection of data ever reported on this subject (almost 100 000 cancer cases).
The results of observational data support a strong association between both vitamin B6 dietary intake and PLP blood levels and the risk of cancer from any site, in terms of both high vs low category comparison and dose-response relationship. However, the high degree of between-study heterogeneity does not allow us to draw definitive conclusions on the role of vitamin B6 in the development of malignant disease in general. When we considered cancers by site, the most consistent findings were those regarding gastrointestinal tumors (both as single tumors-especially colorectal carcinoma-and as a whole), which are based on a large number of studies (n ¼ 45) and consequently a high number of cases (n ¼ 34 428). For the gastrointestinal tract, the inverse association between cancer risk and both vitamin intake and blood levels was statistically significant across all subgroup analyses (by study design and ethnicity), heterogeneity remaining an issue for intake (moderate level of evidence) but not for blood levels results (high level of evidence, although some limitations should be considered, as discussed below).
Nevertheless, other available data do not appear to be in line with these findings. For example, the evidence from vitamin B6 total intake (dietary and supplements) is overall less convincing, although the association with gastrointestinal cancer risk does remain statistically significant. This observation raises the question of whether vitamin B6 can exert a direct preventive effect against cancer development or if it rather represents an indicator of the presence of other protective micronutrients in a healthy diet. The strong and homogeneous association between cancer risk and vitamin B6 blood levels might tip the balance in favor of a direct role of the vitamin against carcinogenesis. On the other side, another piece of evidence appears to oppose this hypothesis: In fact, the meta-analysis of RCTs testing the cancer-preventive role of vitamin B6 found no proof of such an effect. However, this evidence was graded as low level because of the high risk of bias, which is mainly due to the fact that trials did not test vitamin B6 alone (the co-administration of other vitamins can be regarded as a confounding factor) and because their focus was not cancer (which means that participants had not followed up with the aim of detecting the occurrence of cancer); furthermore, evidence from RCTs regarded the risk of malignancies arising from any site of the body (no meta-analysis could be conducted for single tumor types): In particular, no data were available for gastrointestinal carcinomas, for which the evidence from observational studies is strongest.
Regarding tumors from other sites, the evidence for an association is weaker simply because of lack of evidence (eg, prostate carcinoma); because favorable dietary intake data are not confirmed by PLP levels (eg, breast carcinoma) or vice versa (eg, lung carcinoma); or because positive data existing for intake are coupled with a complete lack of information on PLP levels (eg, upper airway tumors), which calls for further investigation in this field.
Overall, our findings provide two main points: 1) vitamin B6 should be further considered as a risk reduction strategy for gastrointestinal cancers; in particular, dedicated RCTs appear justified, possibly with the enrollment of subjects selected on the basis of their personal risk as determined by already established risk factors, as well as according to their blood levels of PLP; 2) PLP blood levels should be considered a new cancer risk factor and their value as biomarker of cancer predisposition validated in large screening programs, possibly along with other biomarkers such as germline polymorphisms involved in carcinogenesis. As a corollary, the current daily recommended dose of vitamin B6 (1.5 mg) might be revised upwards; alternatively, a diet based on foods rich in this vitamin might be endorsed.
Limitations of the present study must also be acknowledged. The most important is represented by the confounding factors potentially influencing the results; in particular, both vitamin B6 intake and plasma PLP levels might be surrogate markers for the assumption of other dietary nutrients with anticancer effects. This is why some investigators prefer to rely on findings obtained from food studies rather than nutrient studies. In the case of vitamin B6, food containing this vitamin, such as fruit and vegetables, does contain other potential anticancer nutrients; however, vitamin B6 is also present in other food (such as meat) that is associated with an increased cancer risk, which might lead to a balance between opposite effects of nutrients present in vitamin B6-containing food. Overall, the true effect of vitamin B6 (like any other nutrient) remains very difficult to examine separately from that of other nutrients. Analogously, PLP plasma levels have been associated with inflammation, which in turn is associated with cancer risk; therefore, PLP might not be primarily involved in the carcinogenesis process but might rather represent a surrogate of the inflammatory status of a given person: again, discerning between the two conditions is an unmet challenge. These considerations call for the conduction of large studies where all these issues are properly addressed in order to enable investigators to provide clinicians with more robust and possibly definitive evidence on this subject.
Another limitation of the available evidence is that we found no data on some tumor types (such as malignant melanoma and soft tissue sarcomas) and very scarce data on others (such as childhood malignancies), which deserve attention by both basic and clinical researchers. As mentioned above, for other cancers (eg, breast and lung carcinomas) the evidence is not fully consistent. These observations, coupled with the heterogeneity of results that often remain unexplained (especially as regards intake data), suggest that other unveiled factors might act as confounders and should be carefully investigated in order to further dissect and ultimately fully exploit the cancer-protective potential of vitamin B6. For example, single studies demonstrated different vitamin effects on cancer risk based on primary tumor subsets (eg, colon vs rectal cancer [21, 22] ; hormone receptor-positive vs -negative breast cancer [23] ) or in some participants subgroups (eg, women in pre-vs postmenopause [24, 25] ; men vs women [26] ). Moreover, available data did not enable us to address the issue of the relationship between cancer risk and the interaction of vitamin B6 with other micronutrients (eg, vitamin B12, folate, methionine) or germline polymorphisms involved in one carbon metabolism, which has been advocated in some studies (27) (28) (29) (30) .
Finally, we acknowledge that other meta-analyses have been already published on this topic over the past few years. They all focused on single tumor sites (colorectal, breast, and kidney cancer, respectively) and observational studies; ours is the first synopsis in this field (including intervention studies). In one article dedicated to colorectal cancer and published 10 years ago (31) , the authors restricted the search to prospective studies in order to avoid the limits of retrospective design (eg, recall bias); in our work-based on a larger number of studies and participants-we demonstrated that the association is statistically significant in both retrospective and prospective studies; moreover, we extended this observation to other gastrointestinal cancers, for which the evidence can be currently categorized as high. Other investigators could not demonstrate a statistically significant relationship between vitamin intake and breast cancer risk (25) , which is inconsistent with the present study. Yet, some authors did not consider the effect of PLP blood levels (which is instead the source of strong evidence in favor of the protective activity of vitamin B6) (32) , and others based their conclusion regarding the relationship between PLP levels and kidney cancer on a single series (33), a finding we could confirm based on multiple studies.
In conclusion, our work provides both clinicians and researchers with the first comprehensive and quantitative overview of the available evidence that links vitamin B6 to cancer risk. Although observational studies suggest an inverse association between higher intake and blood concentrations of vitamin B6, randomized trials do not support these findings. Further studies are needed to clarify the association between vitamin B6 and cancer risk, particularly gastrointestinal cancers.
